The withdrawal of cerivastatin because of its association with rhabdomyolysis is unlikely to have a negative effect on any of the other statins currently available, experts believe. But it may ...

Bayer's voluntary withdrawal of cerivastatin from the U.S. market led to questions regarding the safety of all hydroxymethylglutaryl–coenzyme A reductase inhibitors, or statins. Myopathy and the ...

Media outlets in the US have highlighted Bayer AG's withdrawal of its blockbuster drug cerivastatin from the shelves. News reports today examine the potential impact on other statins as well as ...

An Aug. 9 article incorrectly said that the cholesterol-lowering drug cerivastatin (Baycol) had a 2.5 percent share of the market for statin drugs at the end of 2000. That was its market share at ...

Bayer's abrupt worldwide withdrawal of Baycol (cerivastatin) in August 2001 came as a surprise given that rhabdomyolysis is a side effect common to all statins.[1][1],[2][2] We questioned whether ...

WASHINGTON, Aug. 8 -- The Food and Drug Administration and Bayer Corp. on Wednesday began a worldwide recall of the cholesterol lowering drug cerivastatin, sold under the Baycol brand name, after ...

The warnings proposed by the consumer group, if adopted, could affect the marketing of statins, which are taken by about 12 million people. In particular, they would make it unlikely the drugs ...

A hypercholesterolemic patient medicated with cerivastatin for 22 days resulted in acute rhabdomyolysis. CYP2C8 and CYP3A4 are the major enzymes responsible for the metabolism of cerivastatin, and ...

Both the drugs are suspects and reported to have caused several deaths in the US and European markets in the recent past. Torrent's decision comes shortly after Bayer AG, the patent holder of ...

Bayer's abrupt worldwide withdrawal of Baycol (cerivastatin) in August 2001 came as a surprise given that rhabdomyolysis is a side effect common to all statins.1, 2 We questioned whether Bayer's ...